Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine.

Richard Friedrich Radlberger^* (Erstautor/-in), I Sakic, Tobias Moser (Co-Autor/-in), Georg Pilz (Co-Autor/-in), Andrea Harrer (Co-Autor/-in), Peter Wipfler (Letztautor/-in)

^*Korrespondierende/r Autor/-in für diese Arbeit

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

5 Quellenangaben (Web of Science)

Originalsprache	Englisch
Seiten (von - bis)	102727
Fachzeitschrift	Multiple Sclerosis and Related Disorders
Jahrgang	48
DOIs	https://doi.org/10.1016/j.msard.2020.102727
Publikationsstatus	Veröffentlicht - 2021

Zugriff auf Dokument

@article{36bbb5c10cd245a4b15ab5e5a664ba87,

title = "Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine.",

keywords = "MULTIPLE-SCLEROSIS, ORAL CLADRIBINE, MS",

author = "Radlberger, {Richard Friedrich} and I Sakic and Tobias Moser and Georg Pilz and Andrea Harrer and Peter Wipfler",

note = "all: Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University, Salzburg, Austria.",

year = "2021",

doi = "10.1016/j.msard.2020.102727",

language = "English",

volume = "48",

pages = "102727",

journal = "Multiple Sclerosis and Related Disorders",

issn = "2211-0348",

}

TY - JOUR

T1 - Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine.

AU - Radlberger, Richard Friedrich

AU - Sakic, I

AU - Moser, Tobias

AU - Pilz, Georg

AU - Harrer, Andrea

AU - Wipfler, Peter

N1 - all: Department of Neurology, Christian Doppler Medical Center, Paracelsus Medical University, Salzburg, Austria.

PY - 2021

Y1 - 2021

KW - MULTIPLE-SCLEROSIS

KW - ORAL CLADRIBINE

KW - MS

U2 - 10.1016/j.msard.2020.102727

DO - 10.1016/j.msard.2020.102727

M3 - Original Article

C2 - 33418308

SN - 2211-0348

VL - 48

SP - 102727

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

ER -